Edison award for cancer diagnosis
Israel’s Ibex Medical Analytics (see previously) was a bronze winner in the Diagnostic Technologies category at the 2024 Edison Awards. Ibex won the award for its Galen Breast HER2 platform, that identifies the protein responsible for the proliferation of cancer cells.
Alzheimer’s researcher sees the light
More about the groundbreaking research of Prof. Shai Rahimipour of Israel’s Bar-Ilan University (see previously). His Alzheimer’s disease target is a soluble amyloid protein that can be destroyed by nanoparticles that generate light when exposed to low-intensity X rays.
Combining software and medicine
Israel’s Remepy is developing tailored therapeutic software for mobile applications. It aims to unlock and trigger brain functions that modulate the immune system and enhance traditional medication. The hybrid digital and physical therapy should optimize the effectiveness of treatments.
US approval for retinal imaging
The US FDA has approved the fully autonomous AI from Israel’s AEYE Health (see previously) that diagnoses referable diabetic retinopathy from retinal images obtained by a handheld camera. Portable screening addresses the leading cause of blindness in the global working population.
Using AI & RNA to deliver therapies
Mana.bio (see previously) presented to the delegates of Technion UK’s tour of Israel. CEO and co-founder Yogev Debbi explained Mana’s drug delivery development, exactly 7 months after moving to its new premises on Oct 8 when 25% of their staff started IDF reserve duty.
Using plant cells to improve health
Israel’s BioHarvest Sciences (see previously) is building an 80,000 square foot campus in Yavne, Israel to house all R&D functions and manufacturing facilities. BioHarvest uses plants to transform the medical, cosmetic, and nutrition industries.
A new strategy for treating multiple myeloma
Israel’s UB-Therapeutics is developing a novel therapy for the treatment of multiple myeloma. Its proteasome degradation inhibitor is a cyclic peptide that directly targets the degradation pathway of the proteasome - overcoming cancer’s resistance to existing proteasome inhibitors.
A new hospital for Beersheva
The Israeli has approved the establishment of a second hospital in the Negev city of Beersheva, The Peres Medical Center is expected to open in 2028 with 600 beds. It will reduce the strain on Beershava’s Soroka Medical Center. It will be operated by the Sheba Medical Center.
Integrated cancer research center
The Technion’s Rappaport Cancer Research Center under construction (see previously) will house interdisciplinary researchers, computer scientists, doctors, data analysts, biotechnologists, chemical engineers, and more, working to develop treatments via discovery and education.
Improving the use of Operating Rooms
Israel’s Opmed.ai has developed an AI optimization platform for healthcare, starting with Operating Rooms. An empty OR carries a cost of $1,000 for each unused hour. Opmed.ai is already used in the US and Israel and is working with leading Health Systems such as Mayo Clinic.